Compare CHMI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | BDSX |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Precision Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 88.3M |
| IPO Year | 2013 | 2020 |
| Metric | CHMI | BDSX |
|---|---|---|
| Price | $2.62 | $11.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.00 | ★ $32.50 |
| AVG Volume (30 Days) | 177.5K | ★ 276.7K |
| Earning Date | 03-05-2026 | 02-26-2026 |
| Dividend Yield | ★ 15.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | $40,202,000.00 | ★ $80,173,000.00 |
| Revenue This Year | N/A | $22.01 |
| Revenue Next Year | $31.73 | $26.81 |
| P/E Ratio | $138.24 | ★ N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $2.17 | $3.44 |
| 52 Week High | $3.68 | $20.40 |
| Indicator | CHMI | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 44.23 | 57.37 |
| Support Level | $2.54 | $9.83 |
| Resistance Level | $2.63 | $11.00 |
| Average True Range (ATR) | 0.06 | 1.13 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 12.00 | 69.05 |
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.